Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An 18-Month Phase Ib/II Multi-Center, Open Label Study to Evaluate the Safety of Intravitreal APL-2 Therapy in Patients With Neovascular Age-Related Macular Degeneration (AMD)

Trial Profile

An 18-Month Phase Ib/II Multi-Center, Open Label Study to Evaluate the Safety of Intravitreal APL-2 Therapy in Patients With Neovascular Age-Related Macular Degeneration (AMD)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs APL 2 (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Apellis Pharmaceuticals
  • Most Recent Events

    • 13 Nov 2018 According to an Apellis Pharmaceuticals media release, the company has implemented a temporary pause in dosing following observations of non-infectious inflammation in patients that the company believe resulted from a single manufacturing lot of APL-2.
    • 27 Aug 2018 Planned End Date changed from 14 Apr 2020 to 30 Apr 2020.
    • 27 Aug 2018 Planned primary completion date changed from 14 Feb 2020 to 31 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top